NEW YORK (GenomeWeb) — Members of the Lung Cancer Mutation Consortium have reported data from more than 1,000 lung cancer patients tested for cancer driver mutations over a period of four years, finding a significant improvement in median survival among patients who received targeted therapy based on their molecular testing results compared to those who did not.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.